Drug Profile
Research programme: retinal disorder therapeutics - Evotec SE
Latest Information Update: 28 Jan 2022
Price :
$50
*
At a glance
- Originator Evotec AG
- Developer Evotec SE
- Class Eye disorder therapies; Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Retinal disorders
Most Recent Events
- 28 Jan 2022 No recent reports of development identified for research development in Retinal-disorders in Germany
- 13 Dec 2017 Evotec AG and DFG-Center for Regenerative Therapies Dresden agree to co-develop therapeutics for Retinal disorders
- 13 Dec 2017 Early research in Retinal disorders in Germany (unspecified route)